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Abstract
Aims Left ventricular (LV) thrombus is increasingly detected in patients with and without ischaemic heart disease due to the
increased availability of cardiac magnetic resonance imaging. Risk factors include anterior ST elevation myocardial infarction,
delayed reperfusion therapy, and non-ischaemic cardiomyopathy with severe LV systolic dysfunction. We aimed to report the
characteristics and outcomes of patients with LV thrombus treated with either vitamin K antagonist (VKA) or direct oral anti-
coagulants (DOAC) with a view to describing differences in efficacy, specifically, subsequent thromboembolic events, thrombus
resolution, and also side effects of therapy including clinically significant bleeding.
Methods and results We conducted a retrospective, observational cohort study of patients diagnosed with LV thrombus be-
tween 1 December 2012 and 30 June 2018 and treated with either DOAC or VKA. We recorded patient demographics, past
medical history, prescribed medications, and baseline investigations. The primary outcomes were rates of thromboembolism
and clinically significant bleeding, with secondary outcomes of thrombus resolution on repeat cardiac imaging, repeat hospi-
talization, and all-cause mortality. During the study period, 84 patients were diagnosed with and managed for LV thrombus. Of
these, 62 received VKA and 22 DOAC including 13 prescribed rivaroxaban, eight apixaban, and one dabigatran. Most patients
75 (89%) were male with an average age of 62 ± 14 years. Ischaemic heart disease was the cause of LV impairment in 73 (87%)
patients. Baseline characteristics were similar between groups at baseline. Most n = 55 (65%) were co-prescribed a single an-
tiplatelet agent and 32 (38%) received dual-antiplatelet therapy. During an average follow-up of 3.0 ± 1.4 years, there were no
statistically significant differences between VKA and DOAC in rates of stroke (2% vs. 0%, P = 0.55), other thromboemboli (2%
vs. 0%, P = 0.55), or clinically significant bleeding (10% vs. 0%, P = 0.13). The average interval to cardiac imaging follow-up was
233 ± 251 days and was not different between groups (P = 0.83), and there was no difference in the rate of resolution of
thrombus (76% vs. 65% P = 0.33). Rehospitalization (50% vs. 45%: P = 0.53) and all-cause mortality (10% vs. 14%; P = 0.61)
were also similar.
Conclusions Our data suggest that DOACs are likely to be at least as effective and safe as VKA for stroke prevention in
patients with LV thrombus and, despite their lack of a licence for this indication, are therefore likely to represent a reasonable
and more convenient option for this setting. The optimal timing and type of anticoagulation for LV thrombus, as well as the
role of screening for high-risk patients, should be tested in prospective, randomized trials.
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In patients receiving DOAC compared to vitamin K antagonist for left ventricular thrombus, there were no differences in the rates of thromboembolism, resolution of throm-
bus, or clinically significant bleeding. Our study supports the use of DOAC in this patient group; further prospective studies are needed to determine the optimal treatment
strategy for LV thrombus.
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Introduction
Left ventricular (LV) thrombus is frequently identified in
patients presenting with anterior ST elevation myocardial
infarction (STEMI) despite primary percutaneous coronary
intervention (PCI). It is detectable by echocardiography in
4–8% of those undergoing reperfusion therapy1,2 but is often
found incidentally by cardiovascular magnetic resonance
imaging (CMR) which has greater sensitivity.3 LV thrombus
is more common in those with large, anterior infarcts4 and
in those who do not receive prompt reperfusion but can also
occur in non-ischaemic cardiomyopathies with severe LV
systolic dysfunction.5
The presence of LV thrombus presents an increased risk of
systemic thromboembolism including stroke in around
10–15% of patients in the absence of anticoagulation.6 In
patients with LV thrombus after acute myocardial infarction,
most thromboembolic events occur within the first
4 months,7 whilst in most cases, thrombus is no longer visible
within 3–6 months.4 Observational studies have demon-
strated a reduced risk of thromboembolism with administra-
tion of vitamin K antagonist (VKA), which until recently have
been the only available treatment option.7
Direct oral anticoagulants (DOAC) are now first-line protec-
tion against thromboembolic events in patients with
non-valvular atrial fibrillation (AF) due to their greater safety,
clinical effectiveness, and more predictable pharmacokinetics
compared to VKA, prompting the inference that DOAC might
perform similarly in reducing the risk of thromboembolism
due to LV thrombus. There have been no prospective trials
comparing the use of DOAC with VKA for LV thrombus, and
international guidelines do not make specific recommenda-
tions about the optimal type of anticoagulant,8 yet anecdot-
ally their use for this indication is increasing.9
Objectives
We aimed to report the characteristics and outcomes of
patients with LV thrombus treated with either VKA or DOAC
with a view to describing differences in efficacy, specifically,
in terms of subsequent thromboembolic events, thrombus




This was a retrospective, observational cohort study,
designed and reported according to the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE)
statement.10
Setting
The study was undertaken at the Leeds Teaching Hospitals
NHS Trust (LTHT) which is a tertiary referral centre for cardi-
ology. LTHT provides primary PCI for the West Yorkshire
region, which has a population of approximately 3.5 million
and has routine access to transthoracic echocardiography
(TTE), contrast TTE, and CMR.
Participants
Patients aged over 18 years cared for at our institution and
diagnosed with LV thrombus between 1 December 2012 and
30 June 2018 were eligible for inclusion. Patients were
excluded if they were treated with low-molecular weight
heparin (LMWH) or were not anticoagulated because of either
chronic organized thrombus or patient preference. Patients
bridged with LMWH until the international normalized ratio
(INR) was therapeutic and subsequently treated with VKA
were not excluded. We also excluded patients receiving
anticoagulation prior to diagnosis for other indications, those
anticoagulated for LV aneurysm without evidence of throm-
bus, and those treated at other institutions. Patients who died
within 30 days of diagnosis in whom data on anticoagulation
and follow-up imaging were not available were excluded from
our analysis. Patients were allocated to receive either DOAC or
VKA based on patient preference, following discussion with
their physician and anticoagulation counselling by clinical
pharmacist. According to our institutional protocol, patients
who received DOAC were made aware that this was an
off-licence use of a licensed medication.
Data sources
Patients were identified by searches of TTE, transoesophageal
echocardiography (TOE), contrast TTE, and CMR databases
for the term ‘thrombus’. Patient records with datasets includ-
ing the word ‘thrombus’ were manually evaluated for
evidence of LV thrombus and scrutinized for inclusion criteria
(Figure 1). The data for each patient were confirmed with
reference to local electronic data systems and the written
medical record.
Variables
Demographic variables collected included patient age, sex,
and ethnicity. Aetiology of LV impairment was classified as
ischaemic cardiomyopathy (ICM), dilated cardiomyopathy
(DCM), hypertrophic cardiomyopathy (HCM), acute myocar-
ditis, or unknown. Recorded predisposing medical history
included diabetes mellitus, hypertension, heart failure,
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smoking history, atrial fibrillation (AF), history of thromboem-
bolism, peripheral arterial disease (PAD), previous stroke or
transient ischaemic attack (TIA), immobility, hospitalization
within the past 12 months, inflammatory disease, active
cancer, and CHA2DS2VASc score. We also collected data on
laboratory investigations including haemoglobin, platelets,
creatinine, and N-terminal pro-B-type natriuretic peptide
(NT-pro-BNP) and cardiac imaging data including left ventric-
ular ejection fraction (LVEF), LV volume, LV internal diameter
in diastole (LVIDd), degree of mitral regurgitation (MR), and
the presence of regional wall motion abnormality (RWMA).
Outcomes
The primary outcomes were thromboembolic events during
the study period and clinically relevant bleeding. Secondary
outcomes were resolution of thrombus on subsequent
imaging, all-cause mortality, and repeat hospitalization.
Statistics
Normally distributed continuous variables are expressed as
mean ± standard deviation, non-normally distributed contin-
uous variables by median and range in parentheses. Discrete
variables are presented as number and percentages in paren-
theses. Comparisons between categorical variables were
compared using χ2 and continuous variables by Student’s
t-test. In all analyses, a P-value of <0.05 was regarded as
statistically significant.
Definitions
Patient ethnicity was classified according to the 2011 Census
for England, Northern Ireland andWales. Ischaemic cardiomy-
opathy was defined as either a myocardial infarction at index
presentation, previous coronary artery bypass grafting, previ-
ous PCI, evidence of inducible ischaemia on non-invasive
imaging or scar suggesting infarction on CMR. Inflammatory
disease was defined as any systemic inflammatory process, in-
cluding but not limited to rheumatoid arthritis, systemic lupus
erythematous, and vasculitis. LVEF was determined by CMR
where possible, or from TTE by Simpson’s biplane where en-
docardial border definition allowed. Mitral regurgitation was
regarded as categorical as either moderate or severe. Repeat
imaging was any cardiac imaging undertaken during follow-up
following diagnosis of LV thrombus, regardless of the docu-
mented indication. Rehospitalization was any admission to
hospital following the index episode, and cardiac admissions
were those in which the primary diagnosis was due to the
cardiology complaint. Clinically relevant bleeding was any
episode of bleeding documented on the hospital medical re-
cord including hospitalization, attendance at the emergency
department, or described in subsequent correspondence
Figure 1 Flow chart to show patient identification and exclusion criteria; 275 patients were treated for LV thrombus during the study period, of whom
84 were included in our analysis.
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during the period of anticoagulation. Resolution of LV throm-
bus on repeat imaging was defined as either no evidence of
thrombus or organization of thrombus.
Ethical considerations
The study protocol was approved by local governance pro-
cesses at LTHT as a retrospective service evaluation (audit)
and therefore did not require specific ethical approval or
patient consent, providing that usual data protection was in
place.Onlymembersof the clinical teamhadaccess to routinely
collected data,whichwere anonymized at the point of analysis.
Results
Patients
Between 1 December 2012 and 30 June 2018, 84 patients
were diagnosed with and managed for LV thrombus in LTHT
(Figure 1). The average length of follow-up was 3.0 ± 1.4 years.
Anticoagulation was ceased in 46 (55%) patients prior to cen-
sorship. The average duration of anticoagulation was
677 ± 568 days and not different between DOAC
(545 ± 368 days) and VKA (724 ± 619 days) (P = 0.21). Of
the patients included in our analysis, 75 (89%) were male
with an average age of 62 ± 14 years. Most were White Euro-
pean (n = 73), and the group included South Asians (n = 5),
East Asians (n = 2), Black-Africans (n = 2), and two patients
who classed themselves as other ethnicities.
Most (n = 73, 87%) had ischaemic heart disease as the
cause of LV impairment leading to thrombus, of whom 29
(35%) patients were diagnosed following myocardial infarc-
tion, following an interval of 5 ± 7 days. Four (5%) had
DCM, three (4%) had HCM, two (2%) developed LV thrombus
following an episode of acute myocarditis, and in two (2%),
the aetiology of LV impairment was unknown. In six patients,
LV thrombus was diagnosed following an initial presentation
of stroke. In one patient, the presentation was acute myocar-
dial infarction due to embolism of LV thrombus into the
circumflex artery. For the remaining patients, LV thrombus
was diagnosed incidentally on routine cardiac imaging.
Treatment of left ventricular thrombus
There was a preference for VKA during the study period,
which was prescribed for 62 (74%) patients, all of whom
received warfarin which was given at a variable dosage to
achieve INR between two and three. Of the 22 (26%) who
received DOAC, 13 were prescribed rivaroxaban (20 mg once
daily), eight prescribed apixaban (5 mg twice daily), and one
dabigatran (150 mg twice daily). The clinical characteristics
of patients allocated to receive DOACs compared to VKA
were similar at baseline, with the exception of lower platelet
count, higher rate of PAD, and greater proportion of patients
of ethnic minorities in the DOAC group (Tables 1 and 2).
Fifty-five patients (65%) were co-administered an antiplatelet
agent, which was aspirin in 48, clopidogrel in 33, and
ticagrelor in 6. Thirty-two (38%) were co-administered dual
antiplatelet therapy (DAPT) alongside anticoagulation.
Thromboembolic events
During anticoagulation, there was one episode of stroke; this
occurred 6 days following diagnosis of LV thrombus in a patient
taking VKA. A second patient who was initially prescribed VKA
developed a stroke following cessation of anticoagulation
(with VKA) following resolution of thrombus on CMR. There
were no significant differences between VKA and DOAC in
rates of stroke (rate 2%vs. 0%, P = 0.55). Other thromboemboli
occurred in one patient taking VKA (rate 2% vs. 0%, P = 0.55).
Clinically significant bleeding
During follow-up, there were six documented cases of clini-
cally significant bleeding, all occurring in patients taking VKA
(rate 10% vs. 0%, P = 0.13) (Table 3). There were three epi-
sodes of gastrointestinal bleeding: one requiring hospitaliza-
tion and blood transfusion and two which were managed
conservatively. There were no instances of intracranial bleed-
ing. Three patients developed epistaxis, none of which
required hospitalization or blood transfusion.
Repeat imaging and resolution of thrombus
Repeat imaging datasets were available for 75 (89%) patients,
20 of whom received DOACs and 55 who received VKA
(Figure 2). The mean duration between diagnosis and repeat
imaging was 233 ± 251 days with no difference between
groups (P = 0.83). There was no evidence of residual throm-
bus in 55 (73%) patients who underwent repeat imaging, 42
of whom receiving VKA and 13 received DOAC (rate 76% vs.
65%, P = 0.33). The imaging modality was the same in 41
(55%), of the 34 patients who underwent a different imaging
modality in 26 instances, the initial diagnosis was made by
CMR, and the subsequent imaging was TTE.
Hospitalization and all-cause mortality
During follow-up, 41 patients were hospitalized. In 16, this was
determined to be cardiovascular, and in 34, the hospitalization
was non-cardiovascular. There were no significant differences
in rates of hospitalization between those receiving DOAC or
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VKA (rate 50% vs. 45%, P = 0.53) (Table 3). Excluding patients
who died within 30 days of diagnosis, there were nine deaths
during longer-term follow-up (Figure 1), with no difference be-
tween treatment groups and death caused by thromboembo-
lism or bleeding (rate 10% vs. 14%, P = 0.61).
Discussion
Key findings
In this single centre retrospective analysis of outcomes fol-
lowing anticoagulation for LV thrombus, there were no signif-
icant differences in the rates of systemic thromboembolism,
resolution of thrombus, or bleeding between patients receiv-
ing DOAC or VKA. Of note, all episodes of clinically significant
bleeding and systemic thromboembolism occurred in the
group receiving VKA.
Treatment duration and repeat imaging
The major risk of LV thrombus is systemic embolization of clot
with distal ischaemia or infarction. Rates of thromboembo-
lism appear to be higher in those with large or mobile
thrombi and those that protrude into the LV cavity.6,11–13
Based upon observational data, it is likely that formal
anticoagulation reduces the risk of embolization, but it is
unclear whether it affects the rate of thrombus
resolution.14
The optimal duration of anticoagulation for LV thrombus is
unknown, and although international guidelines suggest
3–6 months, there are no prospective data to support this
recommendation.8 Repeat imaging following a period of
anticoagulation is recommended to assess for resolution with
the suggestion that organized thrombus is associated with a
lower rate of embolization allowing safe withdrawal of
anticoagulation. In the present study, the interval between
diagnosis and repeat imaging and the duration of
Table 1 Baseline characteristics of patients receiving either DOAC or VKA
All patients (n = 84) DOAC (n = 22) VKA (n = 62) P-value
Demographics
Age 62 ± 14 62 ± 13 62 ± 14 1.0
Male sex 75 (89) 20 (91) 55 (89) 0.77
Ethnicity
White European 73 (87) 16 (73) 57 (92) 0.03
South Asian 5 (6) 3 (14) 2 (3)
East Asian 2 (2) 0 (0) 2 (3)
Black-African 2 (2) 1 (5) 1 (2)
Other ethnicity 2 (2) 2 (9) 0 (0)
Past medical history
Hypertension 27 (32) 9 (41) 18 (29) 0.31
Diabetes mellitus 22 (26) 19 (86) 19 (31) 0.12
Smoking history 38 (49) 10 (45) 28 (50) 0.73
Active cancer 4 (5) 0 (0) 4 (6) 0.22
Heart failure 81 (96) 21 (95) 60 (94) 0.77
Hypercholesterolaemia 13 (15) 4 (18) 9 (15) 0.68
AF 6 (7) 3 (14) 3 (5) 0.17
Peripheral arterial disease 6 (7) 4 (18) 2 (3) 0.02
Stroke/TIA 10 (12) 1 (5) 9 (15) 0.21
Thromboembolism 3 (4) 1 (5) 2 (3) 0.77
Immobility 1 (1) 0 (0) 1 (2) 0.55
Admission in previous 12 months 10 (12) 1 (5) 9 (15) 0.21
Inflammatory disease 0 (0) 0 (0) 0 (0) —
CHA2DS2VASc score 3 (1–8) 3 (1–5) 3 (1–8) 0.49
Medications
Aspirin 48 (59) 9 (41) 39 (65) 0.05
Ticagrelor 6 (7) 0 (0) 7 (10) 0.12
Clopidogrel 33 (39) 11 (50) 22 (35) 0.28
Bisoprolol equivalent dose (mg) 4.6 ± 3.2 4.6 ± 2.9 4.6 ± 3.3 0.98
Ramipril equivalent dose (mg) 4.0 ± 2.9 3.8 ± 2.8 4.1 ± 2.9 0.66
Furosemide equivalent dose (mg) 31 ± 48 43 ± 46 26 ± 48 0.17
Aetiology of heart failure
ICM 73 (87) 18 (82) 55 (89) 0.27
DCM 4 (5) 2 (9) 2 (3)
HCM 3 (4) 2 (9) 1 (2)
Myocarditis 2 (2) 0 (0) 2 (3)
Unknown 2 (2) 0 (0) 2 (3)
Continuous variables are expressed as mean ± standard deviation; categorical variables are presented as number and percentages in
parentheses.
AF, atrial fibrillation; DCM, dilated cardiomyopathy; DOAC, direct acting oral anticoagulant; HCM, hypertrophic cardiomyopathy; ICM,
ischaemic cardiomyopathy; TIA, transient ischaemic attack; VKA, vitamin K antagonist.
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anticoagulation were longer than is recommended. Overall,
89% underwent repeat imaging, with resolution of thrombus
in 73%. However, follow-up imaging modality was the same
as that undertaken at baseline in only 45% of cases, and
the lower use of CMR at follow-up might have overestimated
the rate of thrombus resolution.3
Screening of high-risk individuals
Most patients in our cohort were identified incidentally on
routine imaging. Screening for individuals with anterior STEMI
with apical wall akinesis has been suggested.4 On balance,
CMR or contrast TTE would be the imaging of choice due to
their greater sensitivity than standard TTE for the detection
of LV thrombus.3 However, given the proposed relationship
between thromboembolic risk and thrombus burden, it is
not known whether the risk of thromboembolism from
thrombi too small to be seen on TTE outweighs the risk of
bleeding. This is especially true in those patients who
undergo PCI for anterior STEMI who will usually require
longer-term antiplatelet agents alongside anticoagulation.
In our analysis, we identified six patients whose initial
presentation was a stroke. Three of these patients had a his-
tory of previous anterior STEMI, of whom two had under-
gone TTE showing no evidence of LV thrombus. In the
other STEMI patient, LV thrombus had been correctly diag-
nosed, but subsequent resolution on CMR led to a decision
to stop anticoagulation, and they subsequently developed
a stroke, and a second LV thrombus was diagnosed at this
time. For the three patients without a clear history of
STEMI, two had evidence of previous (silent) anterior infarc-
tion on CMR and one was found to have previously undiag-
nosed DCM.
Table 2 Cardiac imaging variables
Outcome
All patients
(n = 84) DOAC (n = 22)
VA
(n = 62) P-value
LVEF (%) 34 ± 13 31 ± 13 35 ± 13 0.31
LVIDd (mm) 54 ± 8 56 ± 8 53 ± 8 0.21
LV volume
(mL)
232 ± 85 252 ± 80 221 ± 87 0.23
MR 14 (17) 3 (14) 11 (18) 0.66
RWMA 67 (81) 20 (91) 47 (76) 0.14
Location
Apex 76 (95) 19 (90) 57 (97) 0.27
Anterior 4 (5) 2 (10) 2 (3)
Haemoglobin
(g/L)
142 ± 21 145 ± 18 141 ± 22 0.48
Platelets
(×109 per litre)
241 ± 79 211 ± 70 252 ± 79 0.03
Creatinine
(μmol/L)
93 ± 29 100 ± 20 91 ± 31 0.23
BNP (ng/L) 5197 ± 6038 6105 ± 4714 4663 ± 6777 0.56
Continuous variables expressed as mean ± standard deviation, categorical variables as number and percentages in parentheses.
DOAC, direct acting oral anticoagulant; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; LVIDd, left ventricular inter-
nal diameter in diastole; MR, mitral regurgitation; RWMA, regional wall motion abnormality; VKA, vitamin K antagonist.
Table 3 Outcomes in patients with LV thrombus
Outcome All patients (n = 84) DOAC (n = 22) VKA (n = 62) P-value
Stroke 1 (1) 0 (0) 1 (2) 0.55
Other systemic emboli 1 (1) 0 (0) 1 (2) 0.55
Gastrointestinal bleeding 3 (4) 0 (0) 3 (5) 0.29
Intracranial bleeding 0 (0) 0 (0) 0 (0) —
Other bleeding 3 (4) 0 (0) 3 (5) 0.29
Internal to repeat imaging 233 ± 251 244 ± 245 230 ± 255 0.83
Resolution of thrombus 55 (73) 13 (65) 42 (76) 0.33
Hospitalization (all) 41 (49) 10 (45) 31 (50) 0.53
Hospitalization (cardiac) 16 (19) 7 (32) 9 (15) 0.08
Hospitalization (non-cardiac) 34 (40) 6 (27) 28 (45) 0.14
All-cause mortality 9 (11) 3 (14) 6 (10) 0.61
Continuous variables expressed as mean ± standard deviation, categorical variables are presented as numbers and percentages in
parentheses.
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Direct oral anticoagulant for the prevention of
stroke in non-valvular atrial fibrillation
Landmark clinical trials assessing DOAC compared to VKA for
the management of non-valvular AF have demonstrated
overall greater safety and at least similar efficacy at reducing
rates of thromboembolism.15–18 Real world studies have con-
firmed these findings; in a large registry study, the rates of
bleeding were significantly lower (hazard ratio: 0.89; 95%
confidence interval: 0.68–0.92) despite a time-in-therapeutic
range of around 70%, higher than in most clinical trials.19
There are also data to support the use of DOAC to prevent
thromboembolism in those with left atrial thrombus.20,21
Anticoagulation for the prevention of vascular
events in heart failure
Patients with heart failure and reduced ejection fraction
(HFrEF) are at greater risk of thromboembolism in sinus
rhythm and atrial fibrillation, and although VKA reduce this
risk, the benefits are outweighed by bleeding rates.22–25
Despite their increased safety, in severe HFrEF, the risk of
bleeding with DOAC combined with the competing risks of
death from heart failure means there is no clinical benefit.26
However, in stable heart failure and vascular disease, there
is a net clinical benefit from low dose DOAC.27 On the whole,
if the thromboembolic rate is less than 3%, then formal
anticoagulation is of questionable benefit.22 In this study,
the rate of reimaging was low, with ongoing anticoagulation
likely providing little benefit in the absence of another
indication.
Direct oral anticoagulant prescribed alongside
dual antiplatelet therapy
For patients with LV thrombus as a consequence of STEMI,
most will require the co-administration of two antiplatelet
agents. In this study, 65% were co-administered an anti-
platelet agent, and 38% were receiving DAPT. Whilst there
is little evidence to guide the use of triple therapy for LV
thrombus, DAPT is commonly co-administered in those
undergoing PCI who also have non-valvular AF.28 Data from
clinical trials29–31 and observational studies32,33 have shown
improved safety when using DOAC compared to VKA, with
lower rates of bleeding. In our study, three (50%) of those
with significant bleeding were receiving DAPT; overall, the
bleeding rate was low and not significantly different
between groups.
Direct oral anticoagulant for the treatment of left
ventricular thrombus
There are few data supporting the use of DOAC for LV throm-
bus, yet the increased safety and efficacy of these agents in
other settings especially where the thromboembolic risk is
around 3% or greater make their use for thromboprophylaxis
in these high-risk patients a logical consideration. A
single-centre retrospective study including 49 patients with
LV thrombus due to anterior ST-elevation myocardial infarc-
tion found no significant difference in rates of thromboembo-
lism, major bleeding, or thrombus resolution between VKA
and DOACs concluding that DOAC appeared to be safe for
such patients.34 In another retrospective analysis of 98 pa-
tients with LV thrombus, 36% of which were treated with
Figure 2 Flow chart to show repeat imaging and rates of thrombus resolution in patients treated with VKA compared to DOAC. The majority of pa-
tients had some form of follow-up imaging, and there was resolution of thrombus in the majority of cases.
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DOAC; there were no differences in rates of stroke or
systemic embolization, but this study did not report rates of
bleeding or thrombus resolution.35 Meta-summaries of case
reports of patients with LV thrombus receiving non-vitamin
K antagonists with varying numbers of patients (12–41)
reported similar findings. One reported no embolic events
and one episode of non-fatal bleeding event, whilst two
others reported one episode of stroke and one episode of
non-fatal bleeding.9,36,37
Our data are broadly in line with these studies. For the 22
patients receiving DOAC, there were no differences in efficacy
and no adverse safety signal associated in this setting. During
the study period, there were two episodes of stroke, one ep-
isode occurred during a period of anticoagulation with VKA.
This patient developed a left middle cerebral artery embolus,
having been commenced on VKA 6 days previously following
an incidental finding of LV thrombus on CMR. At the time of
stroke, the dosage of VKA was not therapeutic, with an inter-
national normalized ratio of 1.6. It is possible that DOACs
might provide additional protection immediately after initia-
tion compared to VKA whose onset time is longer; however,
in this case, LMWH was co-administered during this time. A
second patient, initially treated with VKA, had resolution of
thrombus on CMR performed at 95 days after anticoagulation
was ceased. This patient subsequently developed a stroke
139 days after stopping anticoagulation and a second LV
thrombus was diagnosed at this time.
Limitations
This study is limited by its retrospective, non-randomized
approach, small sample size, and single centre setting, and
our data should be considered in light of these features.
Patients were allocated to receive DOAC or VKA based on
patient preference following discussion with their physician,
and although groups were similar at baseline, it is feasible
that non-random allocation resulted in unmeasured differ-
ences between groups.
Whilst all patients presenting with a myocardial infarction
at our centre undergo routine screening with TTE, not all
undergo CMR screening for this complication. Those patients
diagnosed with LV thrombus on CMR imaging underwent the
scan as part of their routine care or to confirm the presence
of LV thrombus suspected on TTE. It is well recognized that
CMR is a more sensitive test for LV thrombus and that TTE
will have missed smaller thrombi. Furthermore, imaging
performed soon after STEMI might have preceded the devel-
opment of LV thrombus. Nevertheless, we feel that our data
represent the results of a cohort that represents standard
clinical care.
Repeat imaging was performed at the discretion of the
treating cardiologist, and the lack of a standardized approach
is an additional limitation which may have influenced the rate
of thrombus resolution. Furthermore, the time to repeat im-
aging was longer than is recommended to assess for throm-
bus resolution. However, although we report thrombus
resolution, our primary outcomes were clinical event rates.
The lack of experience with the use of DOAC in patients
with reduced renal function or high body mass may limit
the generalizability of these findings for such patients in
whom VKA with a measurable effect might be the preferred
therapy. Finally, in those with non-ischaemic cardiomyopa-
thies, whose natural history does not include an acute trigger,
it may be difficult to comment on the resolution of thrombus
or optimal duration of anticoagulation.
Conclusions
Our data suggest that DOACs are likely to be at least as effec-
tive and safe as VKA for stroke prevention in patients with LV
thrombus and, despite their lack of a licence for this indica-
tion, are therefore likely to represent a reasonable and more
convenient option for this setting. The optimal timing and
type of anticoagulation, as well as the role of screening for
patients at elevated risk of LV thrombus, should be explored
in prospective, randomized trials.
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